Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
American Journal of Human Genetics|November 27, 2010
Whole-exome-sequencing-based discovery of human FADD deficiencyAlexandre Bolze, Minji Byun, David McDonald, et al.
Blood|September 7, 2013
Indolent T-cell lymphoproliferative disease of the gastrointestinal tractAnamarija M Perry, Roger A Warnke, Qinglong Hu, et al.
The Journal of Molecular Diagnostics : JMD|December 4, 2014
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimensChristopher D Carey, Daniel Gusenleitner, Bjoern Chapuy, et al.
Blood Advances|July 14, 2019
Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motifPeixun Zhou, Alex E Blain, Alexander M Newman, et al.
Acta Neuropathologica Communications|November 21, 2013
Identification of a neuronal transcription factor network involved in medulloblastoma developmentMaria Lastowska, Hani Al-Afghani, Haya H Al-Balool, et al.
Blood|February 9, 2023
Spatial and molecular profiling of the mononuclear phagocyte network in classic Hodgkin lymphomaBenjamin J Stewart, Martin Fergie, Matthew D Young, et al.
Frontiers in Immunology|January 9, 2019
Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working GroupSimon Bomken, Jutte van der Werff Ten Bosch, Andishe Attarbaschi, et al.
Leukemia|October 22, 2021
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphomaAlexander M Newman, Masood Zaka, Peixun Zhou, et al.
Science (New York, N.Y.)|July 21, 2018
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammationDelphine Cuchet-Lourenço, Davide Eletto, Changxin Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced CancerSarah Halford, Gareth J Veal, Stephen R Wedge, et al.
Pageof 5